98.13 USD
▲-1.72+3.52%
盘后 93.35 -1.51%
2026-08-03
市值
$5.92B
市盈率
—
EPS
-1.92
股息率
—
52 周区间
12.84 – 99.00
成交量
621.23K
Beta
-0.16
目标价
148.17
52W 低 12.8452W 高 99.00
价格走势
公司简介
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an...